Ekso Bionics Holdings, Inc.

How big is Ekso Bionics Holdings, Inc.?

As of Jun 18, Ekso Bionics Holdings, Inc. has a market capitalization of 9.36 million, with net sales of 17.55 million and a net profit of -10.79 million over the last four quarters. Shareholder's funds are 12.71 million, and total assets amount to 26.65 million.

Market Cap: As of Jun 18, Ekso Bionics Holdings, Inc. has a market capitalization of 9.36 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 17.55 million, while the sum of Net Profit is -10.79 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the Shareholder's Funds amount to 12.71 million, and the Total Assets are 26.65 million.

What does Ekso Bionics Holdings, Inc. do?

Ekso Bionics Holdings, Inc. designs and sells wearable bionic exoskeletons in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $3 million and a net loss of $3 million, with a market cap of $9.36 million.

Overview:<BR>Ekso Bionics Holdings, Inc. designs, develops, and sells wearable bionic human exoskeletons, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 9.36 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.22 <BR>Return on Equity: -86.08% <BR>Price to Book: 0.74<BR><BR>Contact Details:<BR>Address: 1414 Harbour Way S Ste 1201, RICHMOND CA: 94804-3628 <BR>Tel: ['1 510 9841761', '1 212 8671768'] <BR>Fax: 1 702 8662689 <BR>Website: https://ir.eksobionics.com/

Should I buy, sell or hold Ekso Bionics Holdings, Inc.?

Who are in the management team of Ekso Bionics Holdings, Inc.?

As of March 2022, the management team of Ekso Bionics Holdings, Inc. includes Executive Chairman Steven Sherman, CEO Jack Peurach, and Directors Mary Cloyd, Rhonda Wallen, Theodore Wang, Marilyn Hamilton, and Charles Li. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Ekso Bionics Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Steven Sherman, who serves as the Executive Chairman of the Board.<BR>- Mr. Jack Peurach, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Mary Cloyd, who is a Director.<BR>- Ms. Rhonda Wallen, who is also a Director.<BR>- Dr. Theodore Wang, who serves as a Director.<BR>- Ms. Marilyn Hamilton, who is an Independent Director.<BR>- Dr. Charles Li, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Ekso Bionics Holdings, Inc. technically bullish or bearish?

As of August 12, 2025, Ekso Bionics Holdings, Inc. is in a mildly bearish trend, with daily moving averages indicating bearish signals, while it has outperformed the S&P 500 in the short term but underperformed significantly year-to-date.

As of 12 August 2025, the technical trend for Ekso Bionics Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators including daily moving averages showing a bearish signal, while weekly MACD and KST are mildly bullish. However, the monthly Bollinger Bands and Dow Theory indicate a mildly bearish outlook. <BR><BR>In terms of returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 9.18% and 32.10% respectively, but it has significantly underperformed over longer periods, with a year-to-date return of -53.22% compared to the S&P 500's 12.22%.